Richard Scolyer: A Personal Update Before the Next Treatment Milestone — Progression and Purpose
As he prepares to ride in the Tour de Cure in Tasmania, richard scolyer has offered a candid account of where he stands in his battle with brain cancer. “The truth is I’m going downhill and who knows how much longer I’ve got, ” he said, while also noting, “But I’m doing well – I am still able to have a chat with people which is pretty good when you are losing parts of your brain. “
What is Richard Scolyer’s current health update?
Professor Richard Scolyer revealed a stark contrast between prognosis and resolve. He was told last year that he had months to live, yet he is continuing treatment and public engagement. He has shared that recent treatment and testing by Dr Helen Wheeler’s neurological medical oncology team “went well, ” while also expressing anxiety about his next brain x-ray testing and upcoming treatment discussions. For richard scolyer, the sequence of testing, treatment and waiting for results is the immediate reality, and he has spoken openly about both the limitations and the comforts that remain.
Why is he riding in the Tour de Cure in Tasmania?
The ride is both a personal and public act. Scolyer will be among 180 riders participating in the Tour de Cure in Tasmania, an event that raises funds for cancer research and for support of patients and their families. His participation follows his own recent medical experiences and is presented as a way to channel energy into fundraising and visibility for research. He has noted the timing of his anxiety about testing comes just before he is due to start in the Tour de Cure cycling event, framing the ride as a near-term milestone amid ongoing treatment.
Who is involved in his care and what does the next phase look like?
Richard Scolyer’s recent public posts identify his care team and his professional roles. He is Co-Director of Melanoma Institute Australia, a Professor at the University of Sydney, and a Senior Pathologist at Royal Prince Alfred Hospital. He acknowledged the work of Dr Helen Wheeler and her team in carrying out recent treatment and testing. While Scolyer said the recent procedures went well, he also made clear his apprehension about the next brain x-ray and the treatment decisions that will follow. These clinical steps will determine the next phase of care; Scolyer has framed them as immediate and consequential.
The human side of this story is evident in Scolyer’s own language: a mix of realism about progression—”I’m going downhill”—and a measured gratitude for small capacities that remain, such as the ability “to have a chat with people. ” His choice to ride and to speak publicly ties medical uncertainty to collective action, linking his individual trajectory with broader fundraising for research and patient support.
As he prepares for the Tasmanian ride, the questions he has raised about testing and treatment remain open. The Tour de Cure will gather riders and resources; Scolyer’s participation brings attention and a personal narrative that underlines why the fundraising matters. Whether he crosses the finish line or not, his update stands as both a progress report and a reminder of the human stakes behind clinical milestones.
